FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
FibroBiologics (Nasdaq: FBLG) has filed a patent application for methods using fibroblasts and Tissue Factor-expressing cells to prevent IBMIR-mediated blood clotting in cell therapy treatments. The technology aims to address a major challenge in cell therapy by reducing inflammatory and coagulative responses that can compromise treatment effectiveness and safety. The approach focuses on minimizing complications such as complement activation, immune cell infiltration, and platelet adhesion during intravascular, subcutaneous, and intraperitoneal cell administration. This development could potentially improve the safety and efficacy of cell-based treatments by reducing adverse events and rejection by the body's immune system.
FibroBiologics (Nasdaq: FBLG) ha presentato una domanda di brevetto per metodi che utilizzano fibroblasti e cellule che esprimono il Fattore Tissutale per prevenire la coagulazione del sangue mediata da IBMIR nei trattamenti di terapia cellulare. La tecnologia mira ad affrontare una delle principali sfide della terapia cellulare riducendo le risposte infiammatorie e coagulanti che possono compromettere l'efficacia e la sicurezza del trattamento. L'approccio si concentra sulla minimizzazione delle complicazioni, come l'attivazione del complemento, l'inflitrazione delle cellule immunitarie e l'adesione piastrinica durante l'amministrazione cellulare intravascolare, sottocutanea e intraperitoneale. Questo sviluppo potrebbe migliorare potenzialmente la sicurezza e l'efficacia dei trattamenti basati su cellule riducendo eventi avversi e rigetti da parte del sistema immunitario dell'organismo.
FibroBiologics (Nasdaq: FBLG) ha presentado una solicitud de patente para métodos que utilizan fibroblastos y células que expresan el Factor Tisular para prevenir la coagulación de sangre mediada por IBMIR en tratamientos de terapia celular. La tecnología tiene como objetivo abordar un desafío importante en la terapia celular al reducir las respuestas inflamatorias y coagulativas que pueden comprometer la efectividad y seguridad del tratamiento. El enfoque se centra en minimizar las complicaciones como la activación del complemento, la infiltración de células inmunitarias y la adhesión plaquetaria durante la administración celular intravascular, subcutánea e intraperitoneal. Este desarrollo podría mejorar potencialmente la seguridad y eficacia de los tratamientos basados en células al reducir eventos adversos y el rechazo por parte del sistema inmunológico del cuerpo.
FibroBiologics (Nasdaq: FBLG)는 세포 치료법에서 IBMIR 매개 혈전 형성을 방지하기 위해 섬유아세포 및 조직 인자 발현 세포를 사용하는 방법에 대한 특허 출원을 했습니다. 이 기술은 세포 치료에서 중요한 과제를 해결하기 위해 치료의 효과와 안전성을 저해할 수 있는 염증 및 응고 반응을 줄이는 것을 목표로 하고 있습니다. 접근 방식은 혈관 내, 피하 및 복강 내 세포 투여 중 보 complement 활성화, 면역 세포 침투 및 혈소판 부착과 같은 합병증을 최소화하는 데 초점을 맞추고 있습니다. 이 개발은 면역 시스템에서의 부정적인 사건과 거부 반응을 줄임으로써 세포 기반 치료의 안전성과 효과를 향상할 수 있는 잠재력이 있습니다.
FibroBiologics (Nasdaq: FBLG) a déposé une demande de brevet pour des méthodes utilisant des fibroblastes et des cellules exprimant le Facteur Tissulaire afin de prévenir la coagulation sanguine médiée par IBMIR dans les traitements de thérapie cellulaire. La technologie vise à relever un défi majeur de la thérapie cellulaire en réduisant les réponses inflammatoires et coagulantes qui peuvent compromettre l'efficacité et la sécurité du traitement. L'approche se concentre sur la minimisation des complications telles que l'activation du complément, l'infiltration des cellules immunitaires et l'adhésion des plaquettes pendant l'administration cellulaire intravasculaire, sous-cutanée et intrapéritonéale. Ce développement pourrait potentiellement améliorer la sécurité et l'efficacité des traitements basés sur les cellules en réduisant les événements indésirables et le rejet par le système immunitaire du corps.
FibroBiologics (Nasdaq: FBLG) hat einen Patent-Antrag für Methoden eingereicht, die Fibroblasten und Gewebe-Faktor-exprimierende Zellen verwenden, um IBMIR-vermittelte Blutgerinnung bei Zelltherapien zu verhindern. Die Technologie zielt darauf ab, eine der größten Herausforderungen der Zelltherapie anzugehen, indem sie entzündliche und koagulative Reaktionen reduziert, die die Wirksamkeit und Sicherheit der Behandlung gefährden können. Der Ansatz konzentriert sich darauf, Komplikationen wie die Aktivierung des Komplements, das Eindringen von Immunzellen und die Thrombozytenadhäsion während der intravaskulären, subkutanen und intraperitonealen Zellverabreichung zu minimieren. Diese Entwicklung könnte potenziell die Sicherheit und Wirksamkeit zellbasierter Behandlungen verbessern, indem unerwünschte Ereignisse und Abstoßungen durch das Immunsystem des Körpers reduziert werden.
- Patent application filed for innovative technology to reduce blood clotting in cell therapy
- Potential to improve safety and efficacy of cell-based treatments
- Technology addresses a significant limitation in current cell therapy treatments
- None.
Insights
This patent application represents a significant potential advancement in cell therapy safety and efficacy. The technology addresses IBMIR (Instant Blood-Mediated Inflammatory Reaction), a major hurdle in cell therapy that can cause treatment failure and patient complications. The approach of using fibroblasts to prevent blood clotting and reduce inflammatory responses could have far-reaching implications across multiple therapeutic areas.
The innovation could particularly impact the delivery methods for cell therapies through intravascular, subcutaneous and intraperitoneal routes. If successful, this technology could reduce treatment-related complications and improve patient outcomes. However, it's important to note that this is still in the patent application phase and significant clinical validation will be required to prove its effectiveness.
The company's extensive patent portfolio (160+ patents) and focus on fibroblast-based therapeutics positions them well in the regenerative medicine space. This latest patent application could strengthen their competitive advantage in developing cell therapies for chronic diseases.
HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent and Trademark Office covering methods employing fibroblasts or other Tissue Factor (TF)-expressing cells to prevent IBMIR-mediated blood clotting.
This patent application addresses a critical challenge in cell therapy: the risk of instant IBMIR, which can lead to complications such as complement activation, immune cell infiltration, platelet adhesion and coagulation (clotting) that endanger the effectiveness and safety of cell-based treatment. Reducing inflammatory and coagulative responses has the potential to transform therapeutic protocols for intravascular, subcutaneous, and intraperitoneal cell administration and could provide safer and more effective treatments for patients worldwide.
"This patent application describes how we may be able to improve cell therapies by reducing adverse events and rejection by the body's immune system, potentially eliminating blood clotting triggered by the body's inflammatory response," said Pete O'Heeron, Founder & Chief Executive Officer of FibroBiologics.
"This approach harnesses the natural properties of fibroblasts and other TF-expressing cells to minimize the risks of, and overcome, IBMIR, a well-known limitation in cell therapy treatments," said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. "By reducing the inflammatory responses to therapeutic cells, we have developed a unique approach that can make cell therapy treatments potentially safer and more effective. This advancement exemplifies our goal to transform what is possible in the cell therapy space."
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential of fibroblasts and TF-expressing cells to reduce inflammatory and coagulative responses and adverse events, to potentially eliminate blood clotting triggered by the body’s inflammatory response, to potentially transform therapeutic protocols, to provide safer and more effective treatments, to minimize the risks of, and overcome, IBMIR, and to transform what is possible in the cell therapy space. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
What is the purpose of FibroBiologics' (FBLG) new patent application?
How does FibroBiologics' (FBLG) new technology address IBMIR in cell therapy?
What potential benefits does FibroBiologics' (FBLG) new patent technology offer?
